Amplify ETFs Launches The Amplify Weight Loss Drug & Treatment ETF (THNR)
May 21 2024 - 7:00AM
Amplify ETFs announces the launch of the Amplify Weight Loss Drug
& Treatment ETF (NYSE: THNR), an index-based ETF offering
access to companies at the forefront of developing and marketing
GLP-1 treatments.
Over one billion individuals across the globe are now clinically
obese, drawing significant attention to the obesity epidemic as a
critical public health issue.1 With the rising global focus on
health and wellness coupled with the advances in medical treatments
for weight management, THNR offers investors targeted exposure to a
rapidly advancing segment of the healthcare market.
Research forecasts that the GLP-1 market could grow to $100
billion by 2030.2 The fund represents an opportunity to invest in
the forefront of weight loss drug development and production, areas
poised for significant growth. “The launch of THNR aligns with our
mission to provide innovative thematic investment solutions across
new and existing market segments,” said Christian Magoon, CEO of
Amplify ETFs.
GLP-1 drugs have been in use to treat diabetes for over a
decade. However, recent studies demonstrating a 10-20% reduction in
body weight have prompted a massive surge in demand.3
Pharmaceutical companies are now ramping up production to try to
capture the demand.
GLP-1 therapies offer hope beyond weight loss by potentially
reducing cardiovascular risks, strokes, impulsive behaviors, sleep
apnea, and kidney disease. Magoon notes the potentially significant
impact GLP-1s may have on overall public health, “We view THNR
as not just an investment in high growth pharmaceuticals but as an
investment in a healthier future.”
THNR tracks the VettaFi Weight Loss Drug & Treatment Index
(the “Index”). The Index includes companies categorized as 'drug
manufacturers' and 'enablers'. The Index includes a selection of
companies, from those launching or testing GLP-1 agonist drugs to
those enabling these crucial medical advancements. Enablers are
companies engaged in outsourced development and manufacturing,
measurement and analysis, and/or distribution or administration of
GLP-1 drugs.
The Index allocates 70% to drug manufacturers and the remaining
30% to enablers, with a weighted float-adjusted market cap for each
segment to provide broad exposure and balance. Companies in the
drug manufacturer segment that are at the commercial stage or in
phase 3 trials are capped at 15%, while those in earlier stages are
limited to a 5% weighting. Enablers are capped at 5%. The index is
reconstituted and rebalanced quarterly to maintain alignment with
the dynamic pharmaceutical landscape.
Investors can learn more about THNR at AmplifyETFs.com/THNR.
About Amplify ETFs Amplify ETFs, sponsored by
Amplify Investments, has over $9 billion in assets across its suite
of ETFs (as of 3/31/2024). Amplify ETFs deliver investment
opportunities for investors seeking growth, income, and
risk-managed strategies across a range of actively managed and
index-based ETFs. To learn more visit AmplifyETFs.com.
Sales Contact:Amplify
ETFs855-267-3837info@amplifyetfs.com
Media Contacts:Gregory FCA for Amplify
ETFsKerry Davis610-228-2098amplifyetfs@gregoryfca.com
1https://www.goldmansachs.com/intelligence/pages/anti-obesity-drug-market.html
2
https://www.who.int/news/item/01-03-2024-one-in-eight-people-are-now-living-with-obesity
3
https://www.morganstanley.com/im/en-us/individual-investor/insights/articles/glp1-the-weight-of-speculation.html
Carefully consider the Fund’s investment objectives,
risks, charges, and expenses before investing. This and other
information can be found in the Fund’s statutory and summary
prospectuses, which may be obtained at AmplifyETFs.com. Read the
prospectus carefully before investing.
Investing involves risk, including the possible loss of
principal. There can be no assurance that the Fund’s
investment objectives will be achieved. The fund is new with
limited operating history. Shares of any ETF are bought
and sold at market price (not NAV), may trade at a discount or
premium to NAV and are not individually redeemed from the
Fund. The Fund invests in securities included in its Index
regardless of their investment merit and may experience tracking
error: the differences in timing of trades, valuation, plus
fees and expenses between fund and index.
A non-diversified fund can invest a greater portion of its
assets in securities of individual issuers which could cause
greater fluctuations than a diversified fund. A narrowly focused
portfolio concentrated in the pharmaceutical industry or healthcare
sector, may exhibit higher volatility and be vulnerable to factors
affecting them due to regulation, litigation, costs and
competition. Small and/or mid-capitalization companies may be
more vulnerable to adverse general market or economic developments.
Securities issued by foreign companies present risks beyond those
of securities of U.S. issuers.
Amplify Investments LLC serves as the investment adviser to the
Fund. Penserra Capital Management LLC serves as the investment
sub-adviser to the Fund.
Amplify ETFs are distributed by Foreside Fund Services, LLC.